{
  "id": "UCSF_CAPRA_Assessment.v1",
  "gdl_version": "2.0",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "date": "2017-10-09",
      "name": "Syeeda S Farruque",
      "organisation": "Cambio Healthcare Systems",
      "email": "models@cambiocds.com"
    },
    "other_contributors": [
      "Dennis Forslund, Cambio Healthcare Systems"
    ],
    "lifecycle_state": "Author draft",
    "details": {
      "sv": {
        "id": "sv",
        "purpose": "Prognostisk värdering av prostatacancer med hjälp av olika kliniska parametrar.",
        "keywords": [
          "prostatacancer",
          "PSA",
          "UCSF CAPRA",
          "gleason",
          "gleason score"
        ],
        "use": "Maximal poängsumma uppgår till 10p, och baseras på följande parametrar:\nGradering enligt Gleason\nPSA-värde vid diagnos\nÅlder \nKliniskt cancerstadium: antingen 1/2 eller 3a\nAntal procent positiva biopsier\n\nRekommenderad åtgärd:\n- vid mycket låg risk, överväg rutinmässig kontroll\n- vid låg-mellan risk, överväg lokal behandling (kirurgi eller strålning, brachyterapi)\n- vid mellan-hög risk, överväg multimodal/kombinerad behandling (kirurgi med strålning, eller strålning och hormonell behandling)\n- vid mycket hög risk, överväg antingen multimodal/kombinerad ELLER hormonell behandling, samt kliniska prövningar\n\n\nResultatet tolkas enligt:\n                                    Metastasfritt intervall              Överlevnad, prostatacancer    Överlevnad, totalt\n                                    % sannolikhet (95% CI) \t % sannolikhet (95% CI)                        % sannolikhet (95% CI)\nCAPRA Risk Group       5 år \t    10 år                         5 år\t            10 år \t                      5 år \t         10 år\n\nLåg risk                       99.3             97.5                         99.7              97.1                                92.5                   71.4\n(0-2 poäng) \t\n\nMellanrisk                    96.9            93.3                          98.6               91.6                               90.2                   59.7\nGroup (3-5 poäng)\n\nHög risk                       90.4            83.4                          93.4               79.1                               78.7                  42.0 \n(≥6 poäng)\n",
        "misuse": "Ej avsedd för diagnostik.",
        "copyright": "© Cambio Healthcare Systems"
      },
      "en": {
        "id": "en",
        "purpose": "The UCSF (University of California, San Francisco CAPRA (CAncer of the Prostate Risk Assessment) Score uses PSA values and Gleason score grades/patterns among other indicators, to help predict prognosis for patients with prostate cancer.",
        "keywords": [
          "prostate cancer",
          "PSA",
          "The UCSF CAPRA score for prostate cancer risk"
        ],
        "use": "This tool evaluates the risk of Prostate cancer and provides 5 and 10 year survival rates as well as overall recommendations per risk level.\n\nManagment:\n\n- For very low risk patients, consider routine surveillance.\n- For low to intermediate-risk patients, consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy).\n- For intermediate to high-risk patients, consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).\n- For very high-risk patients, consider either multimodal therapy OR hormonal therapy, and clinical trial enrollment.\n\n\nScore interpretation:\n                                    Metastasis-free interval              Prostate cancer–specific survival    Overall survival\n                                    % likelihood (95% CI) \t                % likelihood (95% CI)                        % likelihood (95% CI)\nCAPRA Risk Group    5-year \t10-year \t                 5-year \t10-year \t                      5-year \t         10-year\n\nLow Risk Group          99.3             97.5                            99.7              97.1                                92.5                   71.4\n(0-2 points) \t\n\nIntermediate Risk        96.9            93.3                            98.6               91.6                               90.2                   59.7\nGroup (3-5 points)\n\nHigh Risk Group          90.4            83.4                            93.4               79.1                               78.7                  42.0 \n(≥6 points)\n",
        "misuse": "Do not use for diagnostic purposes without also considering a thorough clinical investigation.",
        "copyright": "© Cambio Healthcare Systems"
      }
    },
    "other_details": {
      "references": "Ref. 1: Cooperberg MR, Broering JM, Carroll PR. Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. JNCI Journal of the National Cancer Institute. 2009;101(12):878-887. doi:10.1093/jnci/djp122"
    }
  },
  "definition": {
    "data_bindings": {
      "gt0003": {
        "id": "gt0003",
        "model_id": "openEHR-EHR-OBSERVATION.ucsf_capra_for_prostate_cancer_risk.v1",
        "template_id": "openEHR-EHR-OBSERVATION.ucsf_capra_for_prostate_cancer_risk.v1",
        "type": "INPUT",
        "elements": {
          "gt0006": {
            "id": "gt0006",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0008]"
          }
        }
      },
      "gt0033": {
        "id": "gt0033",
        "model_id": "openEHR-EHR-EVALUATION.ucsf_capra_for_prostate_cancer_assessment.v1",
        "template_id": "openEHR-EHR-EVALUATION.ucsf_capra_for_prostate_cancer_assessment.v1",
        "type": "OUTPUT",
        "elements": {
          "gt0034": {
            "id": "gt0034",
            "path": "/data[at0001]/items[at0004]"
          },
          "gt0035": {
            "id": "gt0035",
            "path": "/data[at0001]/items[at0002]"
          },
          "gt0036": {
            "id": "gt0036",
            "path": "/data[at0001]/items[at0020]"
          },
          "gt0037": {
            "id": "gt0037",
            "path": "/data[at0001]/items[at0028]"
          },
          "gt0038": {
            "id": "gt0038",
            "path": "/data[at0001]/items[at0033]"
          },
          "gt0039": {
            "id": "gt0039",
            "path": "/data[at0001]/items[at0024]"
          },
          "gt0040": {
            "id": "gt0040",
            "path": "/data[at0001]/items[at0032]"
          },
          "gt0041": {
            "id": "gt0041",
            "path": "/data[at0001]/items[at0034]"
          }
        }
      }
    },
    "rules": {
      "gt0022": {
        "id": "gt0022",
        "priority": 6,
        "when": [
          "$gt0006|Total score|==0"
        ],
        "then": [
          "$gt0034|Managment|=0|local::at0011|Consider routine surveillance.|",
          "$gt0035|Risk level|=0|local::at0015|Very low risk|",
          "$gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood|=0|local::at0021|99.3%|",
          "$gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=0|local::at0029|99.7%|",
          "$gt0038|Score interpretation: 5 Year Overall survival % likelihood|=0|local::at0041|92.5%|",
          "$gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood|=0|local::at0025|97.5%|",
          "$gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=0|local::at0038|97.1%|",
          "$gt0041|Score interpretation: 10 Year Overall survival % likelihood|=0|local::at0035|71.4%|"
        ]
      },
      "gt0023": {
        "id": "gt0023",
        "priority": 5,
        "when": [
          "$gt0006|Total score|<=2",
          "$gt0006|Total score|>=1"
        ],
        "then": [
          "$gt0034|Managment|=1|local::at0012|Consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy)|",
          "$gt0035|Risk level|=1|local::at0016|Low risk|",
          "$gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood|=0|local::at0021|99.3%|",
          "$gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=0|local::at0029|99.7%|",
          "$gt0038|Score interpretation: 5 Year Overall survival % likelihood|=0|local::at0041|92.5%|",
          "$gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood|=0|local::at0025|97.5%|",
          "$gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=0|local::at0038|97.1%|",
          "$gt0041|Score interpretation: 10 Year Overall survival % likelihood|=0|local::at0035|71.4%|"
        ]
      },
      "gt0024": {
        "id": "gt0024",
        "priority": 4,
        "when": [
          "$gt0006|Total score|==3"
        ],
        "then": [
          "$gt0034|Managment|=1|local::at0012|Consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy)|",
          "$gt0035|Risk level|=2|local::at0017|Intermediate risk|",
          "$gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood|=1|local::at0022|96.9%|",
          "$gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=1|local::at0030|98.6%|",
          "$gt0038|Score interpretation: 5 Year Overall survival % likelihood|=1|local::at0042|90.2%|",
          "$gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood|=1|local::at0026|93.3%|",
          "$gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=1|local::at0039|91.6%|",
          "$gt0041|Score interpretation: 10 Year Overall survival % likelihood|=1|local::at0036|59.7%|"
        ]
      },
      "gt0028": {
        "id": "gt0028",
        "priority": 3,
        "when": [
          "$gt0006|Total score|<=5",
          "$gt0006|Total score|>=4"
        ],
        "then": [
          "$gt0034|Managment|=2|local::at0013|Consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).|",
          "$gt0035|Risk level|=2|local::at0017|Intermediate risk|",
          "$gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood|=1|local::at0022|96.9%|",
          "$gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=1|local::at0030|98.6%|",
          "$gt0038|Score interpretation: 5 Year Overall survival % likelihood|=1|local::at0042|90.2%|",
          "$gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood|=1|local::at0026|93.3%|",
          "$gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=1|local::at0039|91.6%|",
          "$gt0041|Score interpretation: 10 Year Overall survival % likelihood|=1|local::at0036|59.7%|"
        ]
      },
      "gt0029": {
        "id": "gt0029",
        "priority": 2,
        "when": [
          "$gt0006|Total score|==6"
        ],
        "then": [
          "$gt0034|Managment|=2|local::at0013|Consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).|",
          "$gt0035|Risk level|=3|local::at0018|High risk|",
          "$gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood|=2|local::at0023|90.4%|",
          "$gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=2|local::at0031|93.4%|",
          "$gt0038|Score interpretation: 5 Year Overall survival % likelihood|=2|local::at0043|78.7%|",
          "$gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood|=2|local::at0027|83.4%|",
          "$gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=2|local::at0040|79.1%|",
          "$gt0041|Score interpretation: 10 Year Overall survival % likelihood|=2|local::at0037|42.0%|"
        ]
      },
      "gt0026": {
        "id": "gt0026",
        "priority": 1,
        "when": [
          "$gt0006|Total score|>6"
        ],
        "then": [
          "$gt0036|Score interpretation: 5 Year Metastasis-free interval % likelihood|=2|local::at0023|90.4%|",
          "$gt0037|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=2|local::at0031|93.4%|",
          "$gt0038|Score interpretation: 5 Year Overall survival % likelihood|=2|local::at0043|78.7%|",
          "$gt0039|Score interpretation: 10 Year Metastasis-free interval % likelihood|=2|local::at0027|83.4%|",
          "$gt0040|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=2|local::at0040|79.1%|",
          "$gt0041|Score interpretation: 10 Year Overall survival % likelihood|=2|local::at0037|42.0%|",
          "$gt0035|Risk level|=4|local::at0019|Very High risk|",
          "$gt0034|Managment|=3|local::at0044|Consider either multimodal therapy OR hormonal therapy|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "sv": {
        "id": "sv",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "UCSF CAPRA för prostatacancer - utvärdering",
            "description": "Utvärdering av poäng erhållen i enlighet med USCF CAPRA, en metod för prognostisk värdering av utfall bland patienter som genomgått behandling för prostatacancer.\n"
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Poängsumma",
            "description": ""
          },
          "gt0022": {
            "id": "gt0022",
            "text": "CDS mycket låg risk",
            "description": ""
          },
          "gt0023": {
            "id": "gt0023",
            "text": "CDS låg risk"
          },
          "gt0024": {
            "id": "gt0024",
            "text": "CDS mellanrisk score 3"
          },
          "gt0026": {
            "id": "gt0026",
            "text": "CDS mycket hög risk score > 6"
          },
          "gt0028": {
            "id": "gt0028",
            "text": "CDS mellanrisk score 4-5"
          },
          "gt0029": {
            "id": "gt0029",
            "text": "CDS hög risk score 6"
          },
          "gt0034": {
            "id": "gt0034",
            "text": "Rekommendation",
            "description": ""
          },
          "gt0035": {
            "id": "gt0035",
            "text": "Risknivå",
            "description": ""
          },
          "gt0036": {
            "id": "gt0036",
            "text": "Metastasfritt intervall - 5 år (%)",
            "description": ""
          },
          "gt0037": {
            "id": "gt0037",
            "text": "Överlevnad, prostatacancer - 5 år (%)",
            "description": ""
          },
          "gt0038": {
            "id": "gt0038",
            "text": "Överlevnad, totalt - 5 år (%)",
            "description": ""
          },
          "gt0039": {
            "id": "gt0039",
            "text": "Metastasfritt intervall - 10 år (%)",
            "description": ""
          },
          "gt0040": {
            "id": "gt0040",
            "text": "Överlevnad, prostatacancer - 10 år (%)",
            "description": ""
          },
          "gt0041": {
            "id": "gt0041",
            "text": "Överlevnad, totalt - 10 år (%)",
            "description": ""
          }
        }
      },
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "Ucsf capra assessment",
            "description": "The UCSF CAPRA score for prostate cancer risk provides an outcome prediction for patients with prostate cancer, post treatment"
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Total score",
            "description": "Sum of the individual scores. The score range is 0 to 10"
          },
          "gt0022": {
            "id": "gt0022",
            "text": "Set Very low risk"
          },
          "gt0023": {
            "id": "gt0023",
            "text": "Set Low risk"
          },
          "gt0024": {
            "id": "gt0024",
            "text": "Set Intermediate risk score 3"
          },
          "gt0026": {
            "id": "gt0026",
            "text": "Set Very high risk score > 6"
          },
          "gt0028": {
            "id": "gt0028",
            "text": "Set Intermediate risk score 4-5"
          },
          "gt0029": {
            "id": "gt0029",
            "text": "Set High risk score 6"
          },
          "gt0034": {
            "id": "gt0034",
            "text": "Managment",
            "description": "As the managment of prostate cancer patients is dependant on finer grained categories of risk levels, these have been assigned by splitting Very low risk and Low risk with scores of 0 and 1-2 respectively. For High and Very High risk, the scores are 6-8 and > 8 respectively."
          },
          "gt0035": {
            "id": "gt0035",
            "text": "Risk level",
            "description": "As the managment of prostate cancer patients is dependant on finer grained categories of risk levels, these have been assigned by splitting Very low risk and Low risk with scores of 0 and 1-2 respectively. For High and Very High risk, the scores are 6-8 and > 8 respectively."
          },
          "gt0036": {
            "id": "gt0036",
            "text": "Score interpretation: 5 Year Metastasis-free interval % likelihood",
            "description": "5 Year Metastasis-free interval % likelihood (95% CI)"
          },
          "gt0037": {
            "id": "gt0037",
            "text": "Score interpretation: 5 Year Prostate cancer-specific survival % likelihood",
            "description": "Prostate cancer–specific survival\n% likelihood (95% CI)"
          },
          "gt0038": {
            "id": "gt0038",
            "text": "Score interpretation: 5 Year Overall survival % likelihood",
            "description": "Overall survival % likelihood (95% CI)"
          },
          "gt0039": {
            "id": "gt0039",
            "text": "Score interpretation: 10 Year Metastasis-free interval % likelihood",
            "description": "10 Year Metastasis-free interval % likelihood (95% CI)"
          },
          "gt0040": {
            "id": "gt0040",
            "text": "Score interpretation: 10 Year Prostate cancer-specific survival % likelihood",
            "description": "Prostate cancer–specific survival\n% likelihood (95% CI)"
          },
          "gt0041": {
            "id": "gt0041",
            "text": "Score interpretation: 10 Year Overall survival % likelihood",
            "description": "Overall survival % likelihood (95% CI)"
          }
        }
      }
    }
  }
}